News that a second biosimilar has now been ‘a’ flagged in the absence of an adequate pharmacovigilance program means it is now down to rheumatologists to help their patients navigate the increasingly complex world of biosimilars, the ARA says. On Friday the PBAC announced that they had decided to ‘a’ flag Brenzys and its originator ...
Rheumatologists must navigate patients through complex world of biosimilars
By Nicola Garrett
23 Aug 2016